Our Science

Ibrexafungerp:

Ibrexafungerp was the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.

Ibrexafungerp has been licensed to GSK.

The U.S. Food and Drug Administration (FDA) approved BREXAFEMME® (ibrexafungerp tablets) in June 2021, for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022, for reduction in the incidence of recurrent VVC.